

PATENT

Attorney Docket GGD-31611-PCT-US

#5

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of : Michel Bergeron, et al.  
 Serial No. : 09/980,516  
 Filing Date : November 2, 2001  
 Confirmation No. : 5405  
 For : Methods and Formulations for Targeting Infectious Agents Bearing Host Cell Proteins

**CERTIFICATION UNDER 37 CFR 1.8(a) and 1.10**

I hereby certify that, on the date shown below, this correspondence is being:

**Mailing**

☒ deposited with the United States Postal Service in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231

**37 CFR 1.8(a)**

☐ with sufficient postage as first class mail

**37 CFR 1.10**

☒ As "Express Mail Post Office to Addressee" Mailing Label EL81008265US

**Transmission**

☐ transmitted by facsimile to Fax No \_\_\_\_\_ addressed to Examiner \_\_\_\_\_ at the Patent and Trademark Office.

Date: April 3, 2002

J. R. Hawk

Assistant Commissioner for Patents  
 Washington, D.C. 20231

**INFORMATION DISCLOSURE STATEMENT**

Sir:

In compliance with Applicant's duty of disclosure as set forth in 37 C.F.R. §1.56, listed on the attached equivalent to Form PTO-1449 are those patents, publications and other information known to the Applicant which may be considered material to the patentability of the claims of the above-identified application.

Applicant respectfully requests that the documents listed on the attached Form PTO-1449 be considered by the Examiner, that these references be made of record in the present application, and that an initialed copy of the attached Form PTO-1449 be returned to the undersigned in accordance with MPEP 609.

Respectfully submitted,

Kristine M. Strodthoff

Kristine M. Strodthoff  
 Registration No. 34,259

Dated: April 3, 2002

**P.O. ADDRESS:**

WHYTE HIRSCHBOECK DUDEK S.C.  
 111 East Wisconsin Avenue, Suite 2100  
 Milwaukee, Wisconsin 53202  
 (414) 273-2100  
 Customer No.: 022202

# INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Docket Number (Optional)

GGD-3161 T-US

Application Number

09/980,516

Applicant(s)

BERGERON, Michel G. et al.

Filing Date

November 2, 2001

Group Art Unit

To be assigned

\*EXAMINER  
INITIAL

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Chun, T.-W. et al. (1998). "Early establishment of a pool of latently infected, resting CD4+ T cells during primary HIV-1 infection". Proc. Natl. Acad. Sci. USA. Vol. 95: 8869-8873.

Cantin, R. et al. (1997). "The Presence of Host-Derived HLA-DR1 on Human Immunodeficiency Virus Type 1 Increases Viral Infectivity". Journal of Virology, Vol. 71(3): 1922-1930

Finzi, D. et al. (1997). "Identification of a Reservoir for HIV-1 in Patients on Highly Active Antiretroviral Therapy". Science, Vol 278: 1295-1300.

Finzi, D. et al. (1999). "Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy". Nature Medicine, Vol. 5(5):512-517.

Saarloos, M.-N. et al. (1997). "Detection of HLA-DR Associated with Monocytotropic, Primary, and Plasma Isolates of Human Immunodeficiency Virus Type 1". Journal of Virology, Vol. 71(2): 1640-1643.

Tremblay, M. J. et al. (1998). "The acquisition of host-encoded proteins by nascent HIV-1". Immunology Today, Vol. 19(8): 346-351.

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.